<DOC>
	<DOCNO>NCT00977860</DOCNO>
	<brief_summary>The purpose study determine , low-risk intermediate-risk cohort , rate acute late grade 3 high gastrointestinal genitourinary toxicity observe 24 month follow estimate rate biochemical Disease-Free Survival , Phoenix American Society Therapeutic Radiology Oncology definition , 2 year follow hypofractionated stereotactic body radiation therapy low intermediate risk prostate cancer .</brief_summary>
	<brief_title>Hypofractionated SBRT For Prostate Cancer</brief_title>
	<detailed_description>Radiosurgery ideal treat prostate cancer : - target accuracy static target excellent , error 1mm , - adjust intra-fractional organ motion , reduce volume target PTV therefore dose surround organ , - use one-hundred non-conplanar beam , dose gradient prostate surround tissue may superior achieve conventional linear accelerator , - radiobiology prostate cancer may favor large dose per fraction .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically proven prostate adenocarcinoma Gleason score 27 Biopsy within one year date registration Clinical stage T1bT2b , N0Nx , M0Mx ( AJCC 6th Edition ) Tstage Nstage determine physical exam available image study ( ultrasound , CT , and/or MRI ) Mstage determine physical exam , CT MRI . Bone scan require unless clinical finding suggest possible osseous metastasis . PSA ≤ 20 ng/dL Patients belong one follow risk group : Low : CS T1bT2a Gleason 26 PSA ≤ 10 , Intermediate : CS T2b Gleason 26 PSA ≤ 10 , CS T1bT2b , Gleason 26 PSA ≤ 20 ng/dL , Gleason 7 PSA ≤ 10 ng/dL Prostate volume : ≤ 100 cc Determined use : volume = π/6 x length x height x width Measurement CT ultrasound ≤90 day prior registration . ECOG performance status 01 Completion patient questionnaire : FACTG questionnaire , AUA questionnaire , EPIC26 questionnaire , SHIM questionnaire , Utilization Sexual Medications/Devices questionnaire Consent sign . Prior prostatectomy cryotherapy prostate Prior radiotherapy prostate lower pelvis Implanted hardware material would prohibit appropriate treatment plan treatment delivery , investigator 's opinion . Chemotherapy malignancy last 5 year . History invasive malignancy ( prostate cancer , basal squamous skin cancer ) last 5 year . Hormone ablation two month prior enrollment , treat</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Stereotactic</keyword>
	<keyword>Radiosurgery</keyword>
</DOC>